Abstract
A murine model of dendritic cell (DC)-based genetic immunization to a defined human melanoma antigen (Ag), MART-1/Melan-A (MART-1), was developed. The MART-1 gene was stably transfected into the nonimmunogenic mouse fibrosarcoma cell line NFSA that is syngeneic in C3Hf/Sem/Kam (C3H, H-2k) mice to generate the NFSA(MART1) cell line. In vivo protection from a lethal NFSA(MART1) tumor challenge could be generated by DCs transduced with a recombinant adenovirus (AdV) vector expressing MART-1 (AdVMART1). This model has the following characteristics: (a) immunological specificity and memory, (b) comparable protection for varying transduction multiplicities of infection, cell doses, and sites of DC inoculation but, interestingly, worse protection with increasing numbers of vaccinations, (c) the ability to treat small established tumors, (d) an absolute requirement for CD8 and CD4 T cells, (e) generation of MART-1-specific splenic cytotoxic T lymphocytes, and (f) up-regulation of both T helper type 1 and T helper type 2 cytokines. Genetically engineered DCs presenting defined tumor Ags represent an attractive method to generate effective immune responses.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ribas, A., Butterfield, L., McBride, W. et al. Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells. Cancer Gene Ther 6, 523–536 (1999). https://doi.org/10.1038/sj.cgt.7700076
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700076
Keywords
This article is cited by
-
Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma
Journal for ImmunoTherapy of Cancer (2019)
-
Lessons learned from cancer vaccine trials and target antigen choice
Cancer Immunology, Immunotherapy (2016)
-
Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain
Cancer Immunology, Immunotherapy (2008)
-
Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine
Journal of Translational Medicine (2007)
-
Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells
Cancer Gene Therapy (2005)